drugset / Trial / NCT07233889

Enteral Supplementation With Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules for the Treatment of Hypophosphatemia.

NCT07233889 ↗

Non-randomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this clinical trial is to evaluate the efficacy and safety of Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules for the treatment of participants with mild, moderate, and severe hypophosphatemia. The main questions it aims to answer are: Does enteral supplementation of Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules elevate participants' serum phosphorus? Does enteral supplementation of Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules cause gastrointestinal complications? Participants with hypophosphatemia will receive Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules orally or via nasogastric tube to observe the efficacy and safety of enteral phosphate supplementation. Participants will take Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules daily, with varying doses based on the severity of hypophosphatemia, for a maximum of 14 days. The effect of phosphate supplementation will be assessed daily through blood draws, and their gastrointestinal symptoms will be recorded.

Timeline

Start
2025-11-21
Primary completion
2026-05-31
Completion
2026-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules Unknown 0.306 unknown Oral
Subject Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules Unknown 0.612 unknown Oral
Subject Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules Unknown 0.816 unknown Oral

Indications